Founded in 2022 as a spin-off from the University of Copenhagen, Solid Therapeutics is a preclinical-stage oncology company focused on developing small-molecule therapies for treating solid tumors. Leveraging advanced research, the company aims to create innovative treatments that improve outcomes for patients with challenging cancers.